EGFR and non-small cell lung carcinoma: According to a previous review, Osimertinib and Afatinib were all suggested as possible first-line treatment options for the major uncommon EGFR mutations including G719X/S768I/L861Q.Besides, Osimertinib was the only approved TKI for EGFR T790M-positive NSCLC patients.